Pharnext
Raj has over 28 years of experience in pharmaceutical development, CMC filings, tech transfer, scale-up, and commercialization. Raj previously served as Vice President, General Manager, and site head at Frontida BioPharm. Throughout his career, Raj has successfully led the development, and optimization, and launch of Xtampza ER Capsules, Vimovo® Tablets, Osmolex CR Tablets, and Entocort ER Capsules, and many more complex & patentable clinical-stage molecules.
This person is not in any offices
Pharnext
Pharnext esPharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.